Press releases

Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)

REGULATED INFORMATION – INSIDE INFORMATION alfapump pivotal study for treatment of recurrent or refractory ascites due to liver cirrhosis Optimised clinical trial design of up to 50 patients implanted with alfapump in study cohort and shorter follow-up time for primary endpoint analysis Planned U.S. launch of alfapump moved forward to H1 2022 Proposed rule of...

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

REGULATED INFORMATION – INSIDE INFORMATION First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher sodium removal with DSR vs standard Peritoneal Dialysis (PD) solution Consistent results between treated patients First clinical study of repeated dose DSR with alfapump® (alfapump DSR) planned to commence in...

Sequana Medical announces results of Annual General Meeting of Shareholders

Experienced MedTech Executive Jason Hannon appointed as Non-Executive Director Ghent, BELGIUM – 23 May 2019 (18:00 CEST) – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today...

Sequana Medical to host webcast on 27 May 2019

Company to discuss late-breaking abstract of DSR therapy for volume overload in heart failure presented at the Heart Failure 2019 Congress Ghent, BELGIUM – 21 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart...

Sequana Medical announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis

Further validation builds on U.S. FDA[1] Breakthrough Device status and inclusion in U.K. NICE[2] recommendations and EASL[3] guidelines   Ghent, BELGIUM – 15 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant...

Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress

Ghent, BELGIUM – 30 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that results from the first-in-human single dose DSR (Direct Sodium Removal)...

Sequana Medical announces Annual General Meeting of Shareholders on 23 May 2019

Regulated Information Ghent, BELGIUM – 23 April 2019 (18:00 CEST) – Sequana Medical NV (“Sequana Medical” or the “Company“) (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces that its Annual...

Sequana Medical announces 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 4 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces its business highlights and financial results for the year ended 31 December 2018, prepared...

Sequana Medical Notice of 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 28 March 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, will announce its results for the full year ended 31 December 2018 and outlook for 2019...

Extraordinary General Shareholders’ Meeting to be held on 25 April 2019

Regulated Information Ghent, BELGIUM – 26 March 2019 (19:00 CET) – Sequana Medical NV [Euronext Brussels: SEQUA] (“Sequana Medical”, the “Company”) today invited the holders of securities issued by the Company to attend an extraordinary shareholders’ meeting before notary public on Thursday 25 April 2019. The agenda items of the extraordinary shareholders’ meeting relate to...
1 2 3

Subscribe to our Press Releases

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close